Regina Groves Sells 5,313 Shares of AtriCure (NASDAQ:ATRC) Stock

Key Points

• Director Regina Groves sold 5,313 AtriCure shares at an average price of $54.22, generating approximately $288,071. Her remaining stake totaled 34,546 shares, a 13.33% reduction in ownership.
• AtriCure shares rose to $55.79, near their 52-week high of $56.02, while the company reported quarterly revenue of $153.6 million and earnings of $0.18 per share—above analyst expectations.
• Analysts maintain a “Moderate Buy” consensus with an average price target of $52.00, despite mixed recent rating changes. Institutional investors own approximately 99.11% of the company’s stock.

AtriCure, Inc. (NASDAQ:ATRC - Get Free Report) Director Regina Groves sold 5,313 shares of AtriCure stock in a transaction on Friday, September 11th. The shares were sold at an average price of $54.22, for a total transaction of $288,070.86. Following the completion of the transaction, the director owned 34,546 shares in the company, valued at approximately $1,873,084.12. This trade represents a 13.33% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link.

AtriCure Stock Performance

ATRC traded up $1.25 during trading on Monday, hitting $55.79. The stock had a trading volume of 1,154,686 shares, compared to its average volume of 809,532. The firm has a market capitalization of $2.84 billion, a P/E ratio of 265.68 and a beta of 1.26. The company has a debt-to-equity ratio of 0.14, a quick ratio of 3.19 and a current ratio of 4.22. AtriCure, Inc. has a twelve month low of $25.36 and a twelve month high of $56.02. The company's 50-day moving average price is $42.41 and its 200 day moving average price is $33.56.

AtriCure (NASDAQ:ATRC - Get Free Report) last issued its earnings results on Thursday, July 23rd. The medical device company reported $0.18 earnings per share for the quarter. The business had revenue of $153.60 million for the quarter, compared to the consensus estimate of $151.80 million. AtriCure had a net margin of 1.85% and a return on equity of 2.34%. During the same quarter in the previous year, the firm earned ($0.13) earnings per share. AtriCure has set its FY 2026 guidance at 0.240-0.320 EPS. On average, equities research analysts forecast that AtriCure, Inc. will post 0.29 EPS for the current fiscal year.

Institutional Trading of AtriCure

A number of institutional investors have recently bought and sold shares of ATRC. ProShare Advisors LLC increased its holdings in AtriCure by 6.6% during the 4th quarter. ProShare Advisors LLC now owns 8,819 shares of the medical device company's stock valued at $349,000 after acquiring an additional 543 shares in the last quarter. Allworth Financial LP lifted its holdings in shares of AtriCure by 372.8% in the second quarter. Allworth Financial LP now owns 1,527 shares of the medical device company's stock valued at $43,000 after purchasing an additional 1,204 shares in the last quarter. Rockefeller Capital Management L.P. grew its position in shares of AtriCure by 43.4% in the fourth quarter. Rockefeller Capital Management L.P. now owns 3,983 shares of the medical device company's stock valued at $158,000 after purchasing an additional 1,205 shares during the last quarter. Comerica Bank grew its position in shares of AtriCure by 121.1% in the fourth quarter. Comerica Bank now owns 2,213 shares of the medical device company's stock valued at $88,000 after purchasing an additional 1,212 shares during the last quarter. Finally, Harbor Investment Advisory LLC purchased a new position in shares of AtriCure during the 2nd quarter worth approximately $40,000. 99.11% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analyst Weigh In

A number of research analysts recently weighed in on the company. Raymond James Financial set a $52.00 price objective on AtriCure in a report on Tuesday, July 21st. Zacks Research lowered shares of AtriCure from a "strong-buy" rating to a "hold" rating in a research report on Monday, August 24th. BTIG Research upped their price target on shares of AtriCure from $45.00 to $55.00 and gave the stock a "buy" rating in a research note on Monday, August 24th. Piper Sandler increased their price target on shares of AtriCure from $50.00 to $60.00 and gave the company an "overweight" rating in a report on Thursday, August 27th. Finally, UBS Group reduced their price objective on shares of AtriCure from $55.00 to $50.00 and set a "buy" rating for the company in a research note on Tuesday, July 28th. One investment analyst has rated the stock with a Strong Buy rating, seven have given a Buy rating and four have assigned a Hold rating to the company's stock. According to MarketBeat, AtriCure currently has a consensus rating of "Moderate Buy" and an average price target of $52.00.

About AtriCure

AtriCure, Inc NASDAQ: ATRC is a medical device company focused on the treatment of atrial fibrillation (AF) and related conditions. The company develops, manufactures and sells surgical and minimally invasive technologies designed to restore normal heart rhythm and reduce the risk of stroke associated with AF.

Its product portfolio includes the AtriClip system for excluding the left atrial appendage, the Isolator and Synergy systems for surgical ablation, and the cryoICE system, which uses cryothermal energy in cardiac procedures.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.